<DOC>
	<DOCNO>NCT01921946</DOCNO>
	<brief_summary>A phase Ⅰ study evaluate pharmacokinetic interaction safety fimasartan rosuvastatin healthy male volunteer .</brief_summary>
	<brief_title>To Evaluate Pharmacokinetic Interactions Safety Between Fimasartan Rosuvastatin</brief_title>
	<detailed_description>After subject sign informed consent voluntarily , go screening period within 21 day . As period I , subject Part A take fimasartan 7 day subject Part B take rosuvastatin 7 day . And , wash 7 day , period II , subject Part A B take fimasartan rosuvastatin 7 day . At period , subject Part A blood sample 2nd , 4th , 6th day medication , 7th day 0.25 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48hour medication ( 17 time period , 34 time total ) . At period , subject Part B blood sample 2nd , 4th , 6th day medication , 7th day 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4 , 5 , 8 , 12 , 24 , 48 72hour medication ( 17 time period , 34 time total ) .</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Healthy male subject , age 20 55 year screen . 2 . Body weight ≥ 50 kg within ± 20 % ideal body weight ( IBW ) ( kg ) = { height ( cm ) 100 } * 0.9 3 . No abnormal symptom sign , base medical history physical examination , congenital chronic disease require treatment 4 . Subject consider appropriate participate study investigator , base clinical laboratory test ( serology , hematology , clinical chemistry , urinalysis ) ECG , perform within 3 week prior administration study drug 5 . Subjects must able listen understand detailed statement inform consent , willing decide participate study , follow study direction provide write informed consent 1 . History clinically significant hypersensitivity study drug , drug additive ( yellow no.5 ) . 2 . History illness may affect absorption , distribution , metabolism excretion ( hepatobiliary , renal , cardiovascular , endocrine ( e.g. , hypothyroidism ) , respiratory , gastrointestinal , hematooncology , central nervous system , psychiatric musculoskeletal system ) 3 . Hypotension ( systolic ≤ 100 mmHg diastolic ≤ 65 mmHg ) hypertension ( systolic ≥ 140 mmHg diastolic ≥ 90 mmHg ) , measure screen 4 . Active liver disease , level ALT ( Aspartate Transaminase ) , AST ( Alanin Transaminase ) total bilirubin &gt; 1.5 x upper limit normal 5 . Creatinine clearance &lt; 80 mL/min ( calculate CockcroftGault formula use serum creatinine ) 6 . Evidence hereditary disease , include galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 7 . History gastrointestinal disease ( i.g. , Crohn 's disease , active peptic ulcer ) resection operation may affect absorption study drug ( exclude simple appendectomy herniorrhaphy ) 8 . History major injury , surgical operation , suspect symptom acute illness ( severe infection , trauma , diarrhea vomit ) within 4 week prior first administration study drug 9 . History excessive alcohol abuse ( &gt; 21 units/week , 1 unit=10g=12.5mL pure alcohol ) , subject abstain drink least 3 day prior start study throughout study period , excessive smoking ( &gt; 10 cigarettes/day ) 10 . Use prescribed drug herbal remedy within 2 week , use overthecounter medication within 1 week prior first administration study drug , affect study safety subject opinion investigator 11 . Participation study within 3 month prior first administration study drug ( The finish time previous study day last administration study drug ) 12 . Donation whole blood within 2 month prior first administration study drug , donation blood product within 1 month prior first administration study drug 13 . Abnormal diet may affect absorption , distribution , metabolism excretion drug ( *e.g. , Grapefruit juice ≥ 1L /day within 7 day prior administration study drug ) 14 . Positive serologic test ( HBsAg , HCV Ab , HIV Ag/Ab , VDRL ) 15 . Subject judged inappropriate participate study investigator , base clinical laboratory test ( serology , hematology , clinical chemistry , urinalysis ) reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Fimasartan</keyword>
</DOC>